Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma

7 Feb 2018

Abstract excerpt

The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29411874
DOI: 10.1111/bjh.15122

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myelomaPMID 29411874Read ↗

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancerSemantic proximity Read ↗

Insights into the role of Fc gamma receptors (FcgammaRs) genetic variations in monoclonal antibody-based anti-cancer therapy.Semantic proximity Read ↗

FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population.Semantic proximity Read ↗

Meta-analysis of the association between low-affinity Fcgamma receptor gene polymorphisms and hematologic and autoimmune disease.Semantic proximity Read ↗

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myelomaSemantic proximity Read ↗

Potential role of daratumumab in the treatment of multiple myelomaSemantic proximity Read ↗

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.Semantic proximity Read ↗

Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meetingSemantic proximity Read ↗

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple MyelomaSemantic proximity Read ↗

Effect of FCGR2A and FCGR3A variants on CLL outcome.Semantic proximity Read ↗

Pattern of Use and Efficacy of Daratumumab-based Therapy in Patients With Multiple Myeloma in a Real-world Setting: a Single Institution ExperienceSemantic proximity Read ↗

Current development of Fc gamma receptors (FcγRs) in diagnostics: a reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.